In Europe, nowadays, this combination is approved for CF patients older than 12-years old who are F508del homozygous or F508del with CFTR residual function mutation (P67L, R117C, L206W, R352Q, A455E, D579G, 711þ3A > G, S945L, S977F, R1070W, D1152H, 2789þ5G > A, 3272 26A > G, or 3849þ10kbC > T) (Table 6). The gene discussed is CFTR; the disease is cystic fibrosis.